Retinopathy
0
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programManagement of Diabetes Mellitus Patients With RetinopathyN/A1 trial
Active Trials
MediBeaconGermany - Mannheim
1 programFluorescein sodium and Zeiss FF450 fundus cameraPHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
MediBeaconFluorescein sodium and Zeiss FF450 fundus camera
LKC TechnologiesRETeval color flicker ERG
AstraZenecaManagement of Diabetes Mellitus Patients With Retinopathy
Clinical Trials (3)
Total enrollment: 2,528 patients across 3 trials
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Start: Nov 2025Est. completion: Dec 202610 patients
Phase 1Recruiting
Study of Stimulus Parameters in Flicker Electroretinogram (ERG)
Start: Mar 2015Est. completion: Jul 201518 patients
N/ACompleted
Management of Diabetes Mellitus Patients With Retinopathy
Start: Dec 2008Est. completion: Aug 20092,500 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,528 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.